18678-13-2

Usage

Uses

Used in Pharmaceutical Industry:
2-methylthieno[3,2-d]pyrimidin-4(3H)-one is used as a pharmaceutical compound for its biological activity, which may contribute to the development of new drugs. Its unique structure and potential interactions with biological targets make it a promising candidate for therapeutic applications.
Used in Agrochemical Industry:
In the agrochemical sector, 2-methylthieno[3,2-d]pyrimidin-4(3H)-one is utilized as an active ingredient in the development of pesticides or other agrochemical products. Its biological activity could be harnessed to control pests or diseases in agriculture, thereby enhancing crop protection and yield.
Used in Organic Synthesis:
2-methylthieno[3,2-d]pyrimidin-4(3H)-one serves as a building block in organic synthesis, allowing chemists to create more complex molecules with diverse applications. Its unique structure and functional groups provide a foundation for the synthesis of novel compounds with potential uses in various industries, including materials science, pharmaceuticals, and agrochemicals.
Note: The specific applications and reasons for using 2-methylthieno[3,2-d]pyrimidin-4(3H)-one in different industries are not explicitly provided in the materials. The uses listed above are inferred based on the general potential of heterocyclic organic compounds with biological activity. Further research and development would be required to confirm and expand upon these potential applications.

InChI:InChI=1/C7H6N2OS/c1-4-8-5-2-3-11-6(5)7(10)9-4/h2-3H,1H3,(H,8,9,10)

Upstream product

• 22288-78-4 Methyl 3-aminothiophene-2-carboxylate 
• 75-05-8 acetonitrile 
• 147123-47-5 3-aminothiophene-2-carboxamide 
• 22288-79-5 3-acetylamine-2-thiophenecarboxylic acid methyl ester 
• 1611471-26-1 ethyl 3-amino-2-thiophene-2-carboxylate hydrochloride 
• 62-55-5 thioacetamide 
• 1037297-94-1 3-acetamidothiophene-2-carboxamide 
• 1000-84-6 O-ethyl acetimidate 

Downstream Products

• 319442-16-5 4-chloro-2-methylthieno[3,2-d]pyrimidine 
• 175137-21-0 4-chloro-7-methylthieno[3,2-d]pyrimidine 

Relevant academic research and scientific papers

Discovery of new hit-molecules targeting Plasmodium falciparum through a global SAR study of the 4-substituted-2-trichloromethylquinazoline antiplasmodial scaffold

From 4 antiplasmodial hit-molecules identified in 2-trichloromethylquinazoline series, we conducted a global Structure-Activity relationship (SAR) study involving 26 compounds and covering 5 molecular regions (I – V), aiming at defining the corresponding

Chemical Space Exploration around Thieno[3,2- d]pyrimidin-4(3 H)-one Scaffold Led to a Novel Class of Highly Active Clostridium difficile Inhibitors

Clostridium difficile infection (CDI) is the leading cause of healthcare-associated infection in the United States. Therefore, development of novel treatments for CDI is a high priority. Toward this goal, we began in vitro screening of a structurally diverse in-house library of 67 compounds against two pathogenic C. difficile strains (ATCC BAA 1870 and ATCC 43255), which yielded a hit compound, 2-methyl-8-nitroquinazolin-4(3H)-one (2) with moderate potency (MIC = 312/156 μM). Optimization of 2 gave lead compound 6a (2-methyl-7-nitrothieno[3,2-d]pyrimidin-4(3H)-one) with improved potency (MIC = 19/38 μM), selectivity over normal gut microflora, CC50s > 606 μM against mammalian cell lines, and acceptable stability in simulated gastric and intestinal fluid. Further optimization of 6a at C2-, N3-, C4-, and C7-positions resulted in a library of >50 compounds with MICs ranging from 3 to 800 μM against clinical isolates of C. difficile. Compound 8f (MIC = 3/6 μM) was identified as a promising lead for further optimization.

Thienopyrimidine derivative as an active ingredient a plant disease control agent (by machine translation)

[Problem] in plant disease resistance-inducing gene expression found thienopyrimidine derivative effect, utilizing the thienopyrimidine derivatives, injuries to plant disease organisms[Solution] some of the thienopyrimidine derivatives, such as gene expression in a plant disease-resistance gene to induce PR-a 1, therefore cruciferous vegetables against plant diseases caused by pathogenic bacillus anthracis, exhibiting excellent control effect was found. [Drawing] no (by machine translation)

MONOCYCLIC, THIENO, PYRIDO, AND PYRROLO PYRIMIDINE COMPOUNDS AND METHODS OF USE AND MANUFACTURE OF THE SAME

The present invention provides monocyclic, thieno, pyrido and pyrrolo pyrimidine compounds. Pharmaceutical compositions comprising one or more of these compounds and optionally comprising a pharmaceutically acceptable salt or hydrate of one or more of the compounds are provided. Preferably, these pharmaceutical compositions further comprise at least one pharmaceutically acceptable carrier. Methods of treating a patient having cancer are provided wherein a therapeutically effective amount of one or more of these compounds or pharmaceutical compositions are administered to the patient.

Microwave-assisted synthesis of potent PDE7 inhibitors containing a thienopyrimidin-4-amine scaffold

A series of novel thienopyrimidin-4-amines have been synthesized and evaluated as phosphodiesterase (PDE) inhibitors. A rationale for the observed selectivity against PDE7 has been obtained from molecular modelling studies on the most active compounds. This journal is the Partner Organisations 2014.

THIENO[3,2-D]PYRIMIDINE-6-CARBOXAMIDES AND ANALOGUES AS SIRTUIN MODULATORS

Provided herein are novel substituted thieno[3,2-d]pyrimidine-6-carboxamide sirtuin inhibitors and methods of use thereof. The sirtuin inhibitors may be used for inhibiting a sirtuin-mediated biological process, and, e.g. for treating and/or preventing diseases and disorders including, but not limited to cancer, neurodegenerative disease and inflammation. Also provided herein are pharmaceutical compositions comprising these sirtuin inhibitors and compositions comprising a sirtuin inhibitor in combination with another therapeutic agent.

NEW COMPOUNDS

There is provided compounds of formula I, wherein R1, R2a, R2b, R2c, X, Y, Z, R3 and ring A/B have meanings given in the description, and pharmaceutically-acceptable esters, amides, solvates or salts thereof, which compounds are useful in the treatment of diseases in which inhibition of a protein or lipid kinase (e.g. PI3-K, particularly class I PI3K, PIM family kinase and/or mTOR) is desired and/or required, and particularly in the treatment of cancer. The invention also relates to combinations containing such compounds.

Antagonists of the human adenosine A2A receptor. Part 1: Discovery and synthesis of thieno[3,2-d]pyrimidine-4-methanone derivatives

The (-)-(11R,2′S)-enantiomer of the antimalarial drug mefloquine has been found to be a reasonably potent and moderately selective adenosine A2A receptor antagonist. Further investigation of this compound has led to the discovery of a series of keto-aryl thieno[3,2-d]pyrimidine derivatives, which are potent and selective antagonists of the adenosine A2A receptor. These derivatives show selectivity against the A1 receptor. Furthermore, some of these compounds have been shown to have in vivo activity in a commonly used model, suggesting the potential for the treatment of Parkinson's disease.

N-aryl-thienopyrimidin-4-amines and analogs as activators of caspases and inducers of apoptosis and the use thereof

Disclosed are N-aryl-thienopyrimidin-4-amines and analogs thereof, represented by the Formulae I-II: wherein Ar and R1-R4 are defined herein. The present invention relates to the discovery that compounds having Formulae I-II are acti

N-ALKYL-N-ARYL-THIENOPYRIMIDIN-4-AMINES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF

Disclosed are N-alkyl-N-aryl-thienopyrimidin-4-amines and analogs thereof, represented by the Formulae I-II: wherein Ar, R1 -R4 and R10 are defined herein. The present invention relates to the discovery that compounds havi